Puromycin (2HCl), an aminonucleoside antibiotic, inhibits protein synthesis. Puromycin (2HCl), an analog of the 3' end of aminoacyl-tRNA, causes premature termination of translation by being linked non-specifically to growing polypeptide chains. Puromycin acting as a non-inhibitor at very low concentration (e.g. 0.04 microM) can bond only to full-length protein at the C-terminus. Puromycin and its derivatives at concentrations lower than those able to compete effectively with aminoacyl-tRNA can bond specifically to full-length protein at a stop codon[3]. Puromycin is a peptidyl nucleoside endowed with significant antibiotic and anticancer properties, but also with an unfortunate nephrotoxic character that has hampered its use as a chemotherapeutic agent[4]. Moreover, puromycin is a damaging agent known to induce apoptosis in mammalian cells. Puromycin-induced apoptosis in S. cerevisiae[5]. Carbocyclic puromycin was equal to puromycin when evaluated for cytotoxicity using P-388 mouse lymphoid leukemia cells in culture[6].
Puromycin 2HCl/嘌呤霉素二盐酸盐 细胞研究
细胞系
浓度
检测类型
检测时间
活性说明
数据源
HEK239 cells
Cytotoxic assay
72 h
Cytotoxicity against HEK239 cells after 72 hrs by Alamar blue assay, IC50=0.42 μM.
20558060
human hepatocellular carcinoma cell line (Huh7)
Cytotoxic assay
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7), CC50=6.63 μM.
18579783
human HepG2 cells
Growth inhibition assay
72 h
Growth inhibition of human HepG2 cells after 72 hrs by SRB assay, IC50=0.21 μM.
18512984
human HepG2 cells
Growth inhibition assay
72 h
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay, IC50=0.23 μM.
搜索
